Arie Belldegrun

Arie S. Belldegrun (born 1949), FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

Belldegrun was born in Tel Aviv, Israel.

He received his medical degree from the Hadassah Medical Center at Hebrew University of Jerusalem in 1974, and conducted his post-graduate studies at the Weizmann Institute of Science in 1979.

He completed his urologic surgery residency at Harvard Medical School in 1985, and his Surgical Oncology fellowship at the National Cancer Institute in 1988.

He is certified by the American Board of Urology, and is a fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons.

Belldegrun is the director of the UCLA Institute of Urologic Oncology, professor of urology, and chief of the Division of Urologic Oncology at the David Geffen School of Medicine.

In 1996, Belldegrun established his first company, Agensys, which was an early-stage privately held biotechnology company based in Los Angeles.

The company was focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets.

He served as its founding chairman of the board of directors from 1996 to 2002, and then as a director.

In 2003, Belldegrun became the founding vice-chairman of the board of directors and chairman of the scientific advisory board of Cougar Biotechnology; the company had a focus in the field of oncology.

In December 2007, Agensys was acquired by Astellas Pharma in a deal valued at US$537 million.

In 2008, Belldegrun became the chairman and partner of Two River, a New York-based venture capital firm and merchant bank focused on the life science sector.

Two River specializes in investments in life science, biotechnology, and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology, cardiovascular disease, neurological disorders, and companion animal health care.

Belldegrun is the founder, chairman, president and CEO of Kite Pharma.

In July 2009, Cougar Biotechnology was acquired by Johnson & Johnson in a $970 million transaction.

Although founded in 2009, the company went public in June 2014.

Based in Santa Monica, Kite Pharma is a commercial-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous T cell therapy (eACT) designed to restore the immune system's ability to recognize and eradicate tumors.

In April 2011, the United States Food and Drug Administration approved abiraterone acetate (Zytiga), Cougar's lead product, for late-stage prostate cancer.

On August 28, 2017, Gilead Sciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal, equating to $180 cash per share.

The deal added CAR-T candidate to Gilead's existing portfolio.

The acquisition was completed in October 2017.

In October 2017, Kite Pharma's therapy, Yescarta (axicabtagene ciloleucel) became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

In 2017, Belldegrun became the co-founder and senior managing director of Vida Ventures, a Boston-based life sciences investment firm that consists of scientists, physicians, entrepreneurs, and investors passionate about building and funding breakthroughs in biomedicine.

Vida Ventures has a bicoastal presence.

In June 2021, Vida Ventures closed its third fund (Vida Ventures III) with $825 million.

Vida Ventures currently has approximately $1.7 billion in assets under management.

In 2017, Belldegrun co-founded and serves as the executive chairman of Allogene Therapeutics, a San Francisco-based biotechnology company.

Allogene has raised $300 in Series A fundraising, and $120 million in a private financing round.

On October 11, 2018, Allogene Therapeutics raised $324 million in an initial public offering on the NASDAQ, listing under the ticker "ALLO".

In July 2019, it was reported that Bellco Capital, Belldegrun's family office, has entered into a joint venture with Tishman Speyer to start Breakthrough Properties.

Belldegrun serves as the co-chairman, while his son, Dan, is the company's CEO.

The company purchased its first property in Boston's Seaport District for $80 million.

In November 2020, Breakthrough Properties closed its first fund (Breakthrough Life Science Property Fund) with $1 billion.

In May 2021, it was reported that Belldegrun's Bellco Capital is co-sponsoring the $2.5 billion merger of Ginkgo Bioworks with Soaring Eagle Acquisition Corp. (a SPAC), with a pre-money valuation of $15 billion.

Ginkgo Bioworks is now trading on the NYSE under the ticker "DNA".

Belldegrun serves on the board of directors of Ginkgo Bioworks.

Belldegrun also serves on the board of directors of Kronos Bio, Fosun Kite, UroGen Pharma, Pontifax, ByHeart and IconOVir Bio.

In the past, he served on the board of directors of Teva Pharmaceuticals, Cell Design Labs, Arno Therapeutics, SonaCare Medical, Roei Medical Technologies, Oncura, Nile Therapeutics, Hana Biosciences, Paramount Acquisition Corp and Chem Rx Corp.

Belldegrun is married to Rebecka Belldegrun and together they have four children.

They reside in Bel Air, Los Angeles.